Hillsdale Investment Management Inc. Purchases 600 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Hillsdale Investment Management Inc. lifted its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX) by 2.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,250 shares of the biopharmaceutical company’s stock after purchasing an additional 600 shares during the period. Hillsdale Investment Management Inc.’s holdings in Royalty Pharma were worth $619,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Brooklyn Investment Group increased its stake in Royalty Pharma by 1,006.9% during the 4th quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 876 shares in the last quarter. Allworth Financial LP boosted its stake in Royalty Pharma by 417.6% in the fourth quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 877 shares during the last quarter. Riverview Trust Co grew its stake in shares of Royalty Pharma by 3,953.3% during the 4th quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 1,186 shares during the period. Fifth Third Bancorp raised its position in shares of Royalty Pharma by 187.1% in the fourth quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 997 shares during the period. Finally, Rakuten Securities Inc. lifted its holdings in Royalty Pharma by 160.5% during the 4th quarter. Rakuten Securities Inc. now owns 1,628 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 1,003 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors.

Royalty Pharma Price Performance

Shares of Royalty Pharma stock opened at $33.75 on Tuesday. The company has a fifty day moving average of $32.33 and a 200-day moving average of $28.75. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. Royalty Pharma plc has a 52-week low of $24.05 and a 52-week high of $34.20. The stock has a market capitalization of $19.46 billion, a price-to-earnings ratio of 23.28, a price-to-earnings-growth ratio of 2.31 and a beta of 0.47.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Equities research analysts expect that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 10th. Investors of record on Friday, February 21st were issued a $0.22 dividend. The ex-dividend date was Friday, February 21st. This represents a $0.88 annualized dividend and a yield of 2.61%. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.21. Royalty Pharma’s payout ratio is 60.69%.

Analyst Upgrades and Downgrades

Separately, TD Cowen raised Royalty Pharma to a “strong-buy” rating in a report on Tuesday, December 24th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Royalty Pharma has an average rating of “Buy” and an average price target of $41.60.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.